SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SKK Holdings Ltd. operates as a holding company, which engages in the provision of civil engineering services in subsurface utility works, including power and telecommunication cable laying, water pipeline and sewer rehabilitation works. The company was founded by Chun Seong Ng and Koon Kiat Sze on October 16, 2013 and is headquartered in Singapore.

SKK Holdings Ltd. - Ordinary Shares - Class A

SKK Holdings Ltd

SKK Holdings is experiencing extreme volatility following the announcement of a massive drone asset acquisition, fueling a polarized debate between traders chasing the potential of its thin-float momentum and those warning of significant dilution risks. The stock has become a focal point for day traders and scalpers, drawing intense discussion over its parabolic price swings, the impact of the acquisition on shareholder value, and concerns regarding its long-term stability.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is gaining momentum as community members discuss a potential supply shock driven by active token burns and anticipation surrounding upcoming network developments. Investors are closely monitoring market volume and the large holdings of major exchange figures, fueling speculation about a significant comeback story.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following the release of extended Phase 3 clinical data for its prostate cancer therapeutic, which has triggered heightened investor interest and speculation regarding potential buyout valuations. The community is actively debating the significance of the data and the company's path toward BLA submission while navigating intense short-interest volatility.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to hyperscaler earnings reports that confirm a massive, sustained surge in AI infrastructure spending, with the company seen as a primary beneficiary of the industry's compute bottleneck. The community remains focused on the firm's accelerating execution and strategic hyperscaler partnerships, with many discussing its potential to re-rate as a leading independent AI cloud provider.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc (CNSP) is trending as investors react to a significant private placement financing, with the community actively debating whether the capital raise serves as a validation of the company's oncology pipeline or a precursor to further dilution. Traders are heavily focused on the stock's low-float mechanics, citing potential for high volatility and momentum-driven price action as market participants monitor key technical levels and short-squeeze possibilities.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is currently trending as investors react to the company's announcement of positive biomarker data and its intent to pursue an FDA accelerated approval pathway for its ALS treatment, CNM-Au8. While the community is actively debating the significance of the upcoming Type C meeting and recent insider activity, many are focused on the long-term potential of the company's nanocatalytic platform across various neurodegenerative indications.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant retail interest as traders bet on a potential short squeeze ahead of upcoming earnings, fueled by high short interest and rising borrow fees. The community remains deeply divided, with bulls pointing to strong AI growth narratives and technical breakout potential, while skeptics warn of volatility and caution against over-leveraging on speculative momentum.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following an unsolicited, non-binding acquisition proposal from GameStop, which has sparked intense debate among traders regarding the deal's ambitious valuation and the significant financing challenges involved. Community discussion is polarized, with some investors viewing the potential synergy as a transformative market move, while many skeptics express strong doubt about the deal's feasibility and potential for shareholder dilution.

Skycorp Solar Group Ltd. is a holding company which designs, develops, manufactures and sells solar PV products and solar power system solutions services, through its indirectly wholly owned subsidiary. Its products include One-stop Solar system, Inverter, LFP Battery, Balcony Storage, and PV Cable. It operates through the following segments: Solar PV Products, High Performance Computing Products, and Others. The Solar PV Products segment includes servers, photovoltaic cable, and photovoltaic connectors. The High Performance Computing Products segment refers to the HPC servers and accessories delivered to the customers. The company was founded on January 19, 2022 and is headquartered in Ningbo, China.

Skycorp Solar Group Ltd. - Ordinary Shares - Class A

Skycorp Solar Group Ltd.

Skycorp Solar Group is experiencing extreme volatility and intense community speculation following news of a strategic acquisition and a private placement, with many traders betting on a short squeeze due to a reported low float and high borrowing fees. While some bulls anticipate a parabolic run toward double-digit price targets, others express caution regarding potential dilution risks and the historical pattern of similar China-based low-float stocks.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing significant momentum driven by legislative progress on the CLARITY Act, which clarifies the regulatory framework for stablecoin reward programs. Investors are actively discussing the stock's role as a critical infrastructure provider in the digital economy, with bullish sentiment supported by rising Bitcoin levels and broader institutional adoption of USDC.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Biotech-focused investor Cormorant Asset Management rebuilt its stake above 6% on Tuesday.</li><li>Cormorant disclosed ownership of 4.36 million shares, up from about 2 million shares in October.</li><li>Retail sentiment flipped to ‘extremely bullish’ from ‘extremely bearish’ on Stocktwits, and message volume surged more than 900%.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. jumped 11% on Tuesday, marking the stock’s biggest rally in over a month, after a biotech-focused investment firm rebuilt its stake amid heightened buzz among retail traders speculating a possible takeover.<h2 class="st-heading-2">Cormorant Lifts MoonLake Stake Above 6%</h2>A Schedule 13G filing on Tuesday showed Cormorant Asset Management reported ownership of 4.36 million Class A ordinary shares in MoonLake Immunotherapeutics, representing a 6.1% stake as of Dec. 31, 2025. The stake increased from about 2 million shares, or 3.14%, disclosed in October 2025 filings, after the firm had previously reduced its position below the 5% reporting threshold.Cormorant Asset Management is a biotech-specialised investment management firm with stakes in Praxis Precision Medicines, BridgeBio Oncology Therapeutics, Edgewise Therapeutics, and Metsera, which was acquired last year by Pfizer, among others.According to data from Quiver Quantitative, the firm reported holdings in 43 stocks as of Sept. 30, 2025, with an estimated portfolio value of about $1.45 billion.<h2 class="st-heading-2">FDA Momentum Builds Around Sonelokimab</h2>Earlier this month, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the company’s lead investigational therapy, Sonelokimab, for moderate-to-severe palmoplantar pustulosis. The company plans to pursue a biologics license application for Sonelokimab in hidradenitis suppurativa in the second half of 2026.Last month, MoonLake said a Type B meeting with the FDA confirmed its clinical evidence strategy for Sonelokimab in hidradenitis suppurativa. Following that update, several brokerages raised price targets or upgraded the stock, though&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-erases-most-of-2025-loses-wall-street-retail-bets-on-fda-feedback-for-sonelokima/cmU1QhGR471">Goldman Sachs</a> downgraded MoonLake to ‘Sell’ last month, citing “high risk” around approvability in hidradenitis suppurativa.The company is scheduled to host an investor day on Feb. 23, at which it plans to provide updates on the clinical development and regulatory pathway for Sonelokimab across multiple inflammatory disease indications.<h2 class="st-heading-2">Stocktwits Buzz Erupts Around MLTX</h2>On Stocktwits, retail sentiment for MLTX flipped to ‘extremely bullish’ from ‘extremely bearish’ over the past day amid over a 900% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_b0740594f9.webp" alt="mltx ss.png" width="971" height="140"><figcaption>MLTX sentiment and message volume as of February 17 | Source: Stocktwits</figcaption></figure>One user said the Cormorant filing has “fundamentally broken” the short thesis. “Cormorant—who knows the science better than anyone—just admitted the "Bear Thesis" was wrong by buying back in at $12-$16.”<stembedurl>https://stocktwits.com/septrading/message/645184471</stembedurl>Another user said, “I can’t stop thinking that we get a PR of some sort, even a little teaser, PM tomorrow AM” ahead of the company’s investor day.<stembedurl>https://stocktwits.com/BOOPIE2020/message/645177386</stembedurl>A third user said, “I have to say that something may be coming..This price action today was solid coupled with the high after hours volume. Someone is accumulating.”<stembedurl>https://stocktwits.com/TDMF123/message/645174457</stembedurl>A separate user said they were watching for either a buyout announcement or positive regulatory news this week, while another argued MoonLake would need to trade higher before attracting interest from a large pharmaceutical acquirer.<stembedurl>https://stocktwits.com/Warren_8/message/645090086</stembedurl><stembedurl>https://stocktwits.com/Newcar/message/645134185</stembedurl>One user pointed to recent travel activity involving Merck’s corporate jet, hinting at a potential takeover by the big pharma firm and noted multiple trips to Zurich, where MoonLake is headquartered.&nbsp;<stembedurl>https://stocktwits.com/Bigpapa46/message/645006814</stembedurl>MLTX stock has risen 33% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Equity

Promising Mid Cap Stocks Worth Watching - November 20th

Direxion Daily TSLA Bull 2X Shares, Metsera, and AltC Acquisition are the three Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies...

Best Medical Stocks To Keep An Eye On - November 20th

Exact Sciences, Metsera, Eli Lilly and Company, UnitedHealth Group, Regeneron Pharmaceuticals, Johnson & Johnson, and Abbott Laboratories are the seven Medical stocks to watch today, according to...

Best Pharmaceutical Stocks To Follow Today - November 20th

Metsera, Eli Lilly and Company, and Regeneron Pharmaceuticals are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of...

Top Mid Cap Stocks To Follow Now - November 19th

Light & Wonder, ProShares UltraPro Short QQQ, Metsera, Direxion Daily TSLA Bull 2X Shares, and AltC Acquisition are the five Mid Cap stocks to watch today, according to MarketBeat's stock screener...

Best Medical Stocks To Watch Now - November 19th

Metsera, Eli Lilly and Company, UnitedHealth Group, Johnson & Johnson, and Boston Scientific are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks...

Best Pharmaceutical Stocks To Follow Today - November 19th

Metsera, Eli Lilly and Company, Pfizer, AbbVie, Regeneron Pharmaceuticals, Novo Nordisk A/S, and AstraZeneca are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...

Best Value Stocks To Follow Now - November 19th

Invesco QQQ, ProShares UltraPro Short QQQ, Metsera, Boeing, Circle Internet Group, Nebius Group, and CoreWeave are the seven Value stocks to watch today, according to MarketBeat's stock screener...

Mid Cap Stocks To Research - November 18th

ProShares UltraPro Short QQQ, Light & Wonder, Metsera, Direxion Daily TSLA Bull 2X Shares, Ondas, AltC Acquisition, and Rigetti Computing are the seven Mid Cap stocks to watch today, according to...

Top Medical Stocks Worth Watching - November 18th

Metsera, UnitedHealth Group, Eli Lilly and Company, Merck & Co., Inc., and Olema Pharmaceuticals are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MTSR News

MTSRMetsera Inc